Next Article in Journal
Reagent Tracker Dyes Permit Quality Control for Verifying Plating Accuracy in ELISPOT Tests
Previous Article in Journal
Intra- and Intercellular Quality Control Mechanisms of Mitochondria
Previous Article in Special Issue
Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessFeature PaperReview
Cells 2018, 7(1), 2; doi:10.3390/cells7010002

Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside

North-Western Tuscany Blood Bank, Pisa University Hospital, via Paradisa 2, 56124 Pisa, Italy
ADIENNE, via Zurigo 46, 6900 Lugano, Switzerland
Authors to whom correspondence should be addressed.
Received: 25 October 2017 / Revised: 20 December 2017 / Accepted: 23 December 2017 / Published: 27 December 2017
(This article belongs to the Special Issue Ten Years of iPSCs: Current Status and Future Perspectives)
View Full-Text   |   Download PDF [646 KB, uploaded 27 December 2017]   |  


Red blood cells and platelets are anucleate blood components indispensable for oxygen delivery and hemostasis, respectively. Derivation of these blood elements from induced pluripotent stem (iPS) cells has the potential to develop blood donor-independent and genetic manipulation-prone products to complement or replace current transfusion banking, also minimizing the risk of alloimmunization. While the production of erythrocytes from iPS cells has challenges to overcome, such as differentiation into adult-type phenotype that functions properly after transfusion, platelet products are qualitatively and quantitatively approaching a clinically-applicable level owing to advances in expandable megakaryocyte (MK) lines, platelet-producing bioreactors, and novel reagents. Guidelines that assure the quality of iPS cells-derived blood products for clinical application represent a novel challenge for regulatory agencies. Considering the minimal risk of tumorigenicity and the expected significant demand of such products, ex vivo production of iPS-derived blood components can pave the way for iPS translation into the clinic. View Full-Text
Keywords: iPS cells; transfusion; red blood cells; platelets iPS cells; transfusion; red blood cells; platelets

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Focosi, D.; Amabile, G. Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. Cells 2018, 7, 2.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top